Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?-Reference-Cited by-同舟云学术

Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?

Published:2015-06-03 Issue:10 Volume:16 Page:1449-1461
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Athyros Vasilios G,Katsiki Niki,Karagiannis Asterios,Mikhailidis Dimitri P

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1053464

Reference123 articles.

1. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

2. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome

3. Chronic Kidney Disease in Japan

4. Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease—Is There a Link?

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different classes;Diabetes, Obesity and Metabolism;2024-03-22

2. The impact of statin use before intensive care unit admission on patients with acute kidney injury after cardiac surgery;Frontiers in Pharmacology;2023-09-14

3. Coronary Artery Disease in CKD-G5D Patients: An Update;Reviews in Cardiovascular Medicine;2023-08-08

4. The bidirectional association between depressive symptoms, assessed by the HADS, and albuminuria–A longitudinal population-based cohort study with repeated measures from the HUNT2 and HUNT3 Study;PLOS ONE;2022-09-15

5. Atorvastatin Restores PPARα Inhibition of Lipid Metabolism Disorders by Downregulating miR-21 Expression to Improve Mitochondrial Function and Alleviate Diabetic Nephropathy Progression;Frontiers in Pharmacology;2022-02-11